|
SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia Clinical research trials and SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia. SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia clinical trial. Subjects frequently obtain the most expert healthcare possible for their SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia  SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
For Condition: Anal Cancer
Status: No longer recruiting
Sponsor(s): AIDS Associated Malignancies Clinical Trials Consortium , National Cancer Institute (NCI)
Synopsis: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. SGN-00101 may be effective in preventing anal cancer. PURPOSE: Phase I/II trial to study the effectiveness of SGN-00101 in preventing anal cancer in HIV-positive patients who have high-grade anal neoplasia.
Details: OBJECTIVES: - Determine the safety and maximum tolerated dose of SGN-00101 in HIV-positive patients with high-grade anal squamous intraepithelial lesions. - Determine clinical response and histologic/cytologic regression in patients treated with this drug. - Determine immune response in patients treated with this drug. - Determine the effect of this drug on HIV viral load and CD4 level in these patients. OUTLINE: This is a dose-escalation study. Patients receive SGN-00101 subcutaneously once on weeks 0, 4, and 8. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 5-6 patients receive escalating doses of SGN-00101 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experience dose-limiting toxicity. Patients are followed at 1, 4, and 10 months. PROJECTED ACCRUAL: A total of 5-18 patients will be accrued for this study within 1-6 months.
Eligibility:
Study Type: Interventional, Prevention
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed high-grade anal squamous intraepithelial lesions (HSIL) with residual HSIL of the anal canal or margin by high-resolution anoscopy - Declined routine surgery or not a candidate for surgical excision of HSIL - Documented evidence of HIV infection by one of the following methods: - Serologic (ELISA or western blot) - Culture - Quantitative polymerase chain reaction or bDNA assays - HIV RNA no greater than 500 copies/mL - CD4 at least 200 x 10^6/L - Must have received stable highly active antiviral therapy (HAART) for at least 4 weeks before study - HAART defined as 3 or more agents, including a protease inhibitor or nonnucleoside reverse transcriptase inhibitor that is approved or available through expanded access combination antiviral therapy - No prior history of invasive anal or cervical cancer - No concurrent untreated cervical HSIL PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Not specified Life expectancy - At least 12 months Hematopoietic - Hemoglobin at least 10 g/dL - Platelet count at least 75,000/mm^3 - Absolute neutrophil count at least 1,000/mm^3 Hepatic - AST and ALT no greater than 3 times upper limit of normal (ULN) Renal - Creatinine no greater than 1.5 times ULN Immunologic - No prior severe allergic reactions (i.e., anaphylactic response) to drugs or any other allergen - No history of collagen-vascular or autoimmune disorder requiring treatment within the past 5 years - No other concurrent illness that compromises the immune system - No active serious opportunistic infection Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use 2 forms of effective contraception during and for 3 months after study - No concurrent participation in a conception process (e.g., active attempt to become pregnant or impregnate, sperm donation, or in vitro fertilization) - No other concurrent medical or psychiatric illness that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy - No concurrent immunostimulants (including interferon or interleukin-12) Chemotherapy - More than 1 year since prior chemotherapy for cancer Endocrine therapy - No concurrent steroids that compromise immune function - Concurrent topical corticosteroids allowed if dose determined not to suppress immune function Radiotherapy - More than 1 year since prior radiotherapy for cancer Surgery - See Disease Characteristics Other - See Disease Characteristics - More than 30 days since other prior investigational agents - No concurrent medications that suppress immune function
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JoelPalefsky, Study Chair, University of California, San Francisco
UCSF Comprehensive Cancer Center
San Francisco, California, 94143
United States
Additional Information:
Study ID Numbers: CDR0000258786; AMC-035
Study Start Date:
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00052897
Other Anal Cancer Studies:
1. SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
2. Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
3. Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients with Primary Anal Cancer
4. Anal Sphincter Prosthesis in Treating Patients Who Are Undergoing Surgery for Anal or Rectal Cancer
Related Studies:
Other Anal Cancer Clinical Trials
Other California Clinical Trials
Other San Francisco Clinical Trials
SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
|
|
|
|
|
|
|
|
